Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2- negative breast cancer
Morales Murillo, Serafín
de la Haba, Juan
MetadataShow full item record
PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early breast cancer. Low risk patients might not need adjuvant chemotherapy since their risk of distant relapse at 10-years is below 10% with endocrine therapy only. In this study, 517 consecutive patients with ER+/HER2- and node-negative disease were evaluated for Ki67 and Prosigna. Most of Luminal A tumors (65.6%) and ROR-low tumors (70.9%) had low Ki67 values (0-10%); however, the percentage of patients with ROR-medium or ROR-high disease within the Ki67 0-10% group was 42.7% (with tumor sizes ≤2 cm) and 33.9% (with tumor sizes > 2 cm). Finally, we found that the optimal Ki67 cutoff for identifying Luminal A or ROR-low tumors was 14%. Ki67 as a surrogate biomarker in identifying Prosigna low-risk outcome patients or Luminal A disease in the clinical setting is unreliable. In the absence of a well-validated prognostic gene expression-based assay, the optimal Ki67 cutoff for identifying low-risk outcome patients or Luminal A disease remains at 14%.
Is part ofOncotarget, 2017, vol. 8, núm. 13, p, 21930-21937
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by (c) Fernandez-Martinez et al., 2017
Showing items related by title, author, creator and subject.
Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response Sánchez Rovira, Pedro; Seguí, M. A.; Llombart, A.; Aranda, Enrique; Antón, Antonio; Sánchez, A.; Lomas, M.; Jaén, A.; Fernández, M.; Porras, I.; Dalmau, E.; Morales Murillo, Serafín; Haba-Rodríguez, J. de la (Springer, 2013)Purpose: The primary aim of this trial was to assess the rate of pathologic complete responses (pCR) of doxorubicin/cyclophosphamide (AC) followed by bevacizumab/docetaxel (BT), as neoadjuvant therapy for breast cancer ...
The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors Landa, Iñigo; Ruiz-Llorente, Sergio; Montero-Conde, Cristina; Inglada-Pérez, Lucía; Schiavi, Francesca; Leskelä, Susanna; Pita, Guillermo; Milne, Roger; Maravall Royo, Javier; Ramos, Ignacio; Andía, Víctor; Rodríguez-Poyo, Paloma; Jara-Albarrán, Antonino; Meoro, Amparo; Peso, Cristina del; Arribas, Luis; Iglesias, Pedro; Caballero, Javier; Serrano, Joaquín; Picó, Antonio; Pomares, Francisco; Giménez, Gabriel; López-Mondéjar, Pedro; Castello, Roberto; Merante-Boschin, Isabella; Pelizzo, Maria-Rosa; Mauricio Puente, Dídac; Opocher, Giuseppe; Rodríguez-Antona, Cristina; González- Neira, Anna; Matias-Guiu, Xavier; Santisteban, Pilar; Robledo, Mercedes (Public Library of Science, 2009)In order to identify genetic factors related to thyroid cancer susceptibility, we adopted a candidate gene approach. We studied tag- and putative functional SNPs in genes involved in thyroid cell differentiation and ...
Moran, Sebastian; Martínez Cardús, Anna; Sayols, Sergi; Musulén, Eva; Balañá, Carme; Estival Gonzalez, Anna; Moutinho, Cátia; Heyn, Holger; Diaz Lagares, Angel; Castro de Moura, Manuel; Stella, Giulia M.; Comoglio, Paolo M.; Ruiz Miró, Maria; Pazo Cid, Roberto; Antón, Antonio; Lopez Lopez, Rafael; Soler, Gemma; Longo, Federico; Guerra, Isabel; Fernandez, Sara; Assenov, Yassen; Plass, Christoph; Morales, Rafael; Carles, Joan; Bowtell, David; Mileshkin, Linda; Sia, Daniela; Tothill, Richard; Tabernero, Josep; Llovet, Josep M.; Esteller, Manel; Matias-Guiu, Xavier (Elsevier, 2016)Cancer of unknown primary ranks in the top ten cancer presentations and has an extremely poor prognosis. Identification of the primary tumour and development of a tailored site-specific therapy could improve the survival ...